title: Inhibition of 19-kDa C-terminal region of merozoite surface protein-1-specific antibody responses in neonatal pups by maternally derived 19-kDa C-terminal region of merozoite surface protein-1-specific antibodies but not whole parasite-specific antibodies.
abstract: Immunizing pregnant women with a malaria vaccine is one approach to protecting the mother and her offspring from malaria infection. However, specific maternal Abs generated in response to vaccination and transferred to the fetus may interfere with the infant's ability to respond to the same vaccine. Using a murine model of malaria, we examined the effect of maternal 19-kDa C-terminal region of merozoite surface protein-1 (MSP1(19)) and Plasmodium yoelii Abs on the pups' ability to respond to immunization with MSP1(19). Maternal MSP1(19)-specific Abs but not P. yoelii-specific Abs inhibited Ab production following MSP1(19) immunization in 2-wk-old pups. This inhibition was correlated with the amount of maternal MSP1(19) Ab present in the pup at the time of immunization and was due to fewer specific B cells. Passively acquired Ab most likely inhibited the development of an Ab response by blocking access to critical B cell epitopes. If a neonate's ability to respond to MSP1(19) vaccination depends on the level of maternal Abs present at the time of vaccination, it may be necessary to delay immunization until Abs specific for the vaccinating Ag have decreased.
authors.affiliation: Queensland Institute of Medical Research and CRC for Vaccine Technology, Brisbane, Australia.
authors.forename: Danielle I
authors.initials: DI
authors.lastname: Stanisic
authors.forename: Laura B
authors.initials: LB
authors.lastname: Martin
authors.forename: Michelle L
authors.initials: ML
authors.lastname: Gatton
authors.forename: Michael F
authors.initials: MF
authors.lastname: Good
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D000913:Antibodies, Protozoan / Q000008:administration & dosage / Q000096:biosynthesis* / Q000494:pharmacology*; D000918:Antibody Specificity; D016175:B-Lymphocyte Subsets / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D002455:Cell Division / Q000276:immunology; D015536:Down-Regulation / Q000276:immunology*; D005260:Female; D007112:Immunity, Maternally-Acquired / Q000276:immunology; D007116:Immunization, Passive; D016130:Immunophenotyping; D018655:Lymphocyte Count; D008431:Maternal-Fetal Exchange / Q000276:immunology*; D020066:Merozoite Surface Protein 1 / Q000008:administration & dosage / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008970:Molecular Weight; D010446:Peptide Fragments / Q000276:immunology* / Q000502:physiology*; D010967:Plasmodium yoelii / Q000276:immunology*; D011247:Pregnancy
chemical_list: D000913:Antibodies, Protozoan; D020066:Merozoite Surface Protein 1; D010446:Peptide Fragments